Tag: Biotech and Pharma

Adjusted earnings per share of $2.59 beat the consensus estimate of $2.53 by $0.06. Revenue reached $25.4 billion, slightly above the $25.38 billion consensus, representing a 5.9% increase from $24.0 billion in the same quarter last year.

Bristol Myers Squibb shares surged 6.5% on Monday following the announcement of positive top-line results from two separate Phase 3 clinical trials evaluating targeted therapies for neuroendocrine tumors and idiopathic pulmonary fibrosis.

Sanofi and Regeneron announced Thursday an expansion of their immunology drug alliance, under which Regeneron will receive $1 billion upfront and be eligible for up to $7 billion in additional milestone payments.

Ξεκίνησε τις πωλήσεις του Durogesic στη γαλλική αγορά η Lavipharm.

Shares in Swedish microcap stock Nanexa more than doubled early Friday after the drug-delivery group revealed a $1.33 billion licensing deal with pharma giant Novo Nordisk.

AbbVie and Iambic Therapeutics announced a multi-year collaboration to apply Iambic’s artificial intelligence platform to small molecule drug discovery 

Novo Nordisk said on Monday its ​next-generation experimental drug, CagriSema, delivered an ‌estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming ​Eli Lilly’s rival drug.

Novo set out its 2030 strategic ambitions at a Capital Markets Day in London on Monday, but the plan failed to satisfy investors hoping for a more decisive turnaround.

Xenon Pharmaceuticals said it submitted a regulatory filing for its lead drug candidate that puts it on the brink of its first commercial product.

Σημαντική αύξηση των ενοποιημένων πωλήσεων προ claw back και rebate κατά 24,1% το α’ εξάμηνο κατέγραψε ο όμιλος Lavipharm ενώ τα κέρδη EBITDA από συνεχιζόμενες δραστηριότητες αυξήθηκαν κατά 5,2%.

Novo Nordisk on Monday said it is rebranding its name to “Novo” and updating its corporate culture, as the company works to win back market share in the obesity drug space. 

 A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker’s board to improve corporate governance after its shares suffered a record fall this week ​following back-to-back trial setbacks.

Novartis AG shares fell over 3% on Monday, after the drugmaker on Friday said its experimental drug pelacarsen failed to reduce the risk of heart attacks, strokes and other serious heart problems in a major late-stage trial, dealing a setback to its cardiovascular drug pipeline.

Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an ‌older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product.

Eli Lilly  continued its acquisition spree on Monday as the world’s largest drugmaker agreed to pay roughly $2.9 billion in cash for a biotechnology company developing treatments for autoimmune diseases.

Moderna plans to raise $2 billion by selling convertible senior notes due 2032, with proceeds earmarked for its cancer vaccine business and debt repayment, the company said Thursday.

Abbott agreed to pay $670 million to resolve a lawsuit over its specialty formulas for premature infants as well as about 2,000 related claims.

An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option.

Coloplast shares climbed 3.5% on Tuesday, after the Danish medical device maker beat sales expectations in its fiscal third quarter, offsetting a miss on profit margins tied to reimbursement setbacks in its Biologics unit and currency headwinds.

AstraZeneca said Monday it is discontinuing a late-stage trial testing its drug volrustomig, combined with chemotherapy, in patients with metastatic non-small cell lung cancer.